{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04283539",
            "orgStudyIdInfo": {
                "id": "ircAE HS-3411"
            },
            "organization": {
                "fullName": "National Jewish Health",
                "class": "OTHER"
            },
            "briefTitle": "Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy",
            "officialTitle": "Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "identification-of-pathways-to-mitigate-immune-related-adverse-events-with-cancer-immunotherapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2020-06-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-02-21",
            "studyFirstSubmitQcDate": "2020-02-21",
            "studyFirstPostDateStruct": {
                "date": "2020-02-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-08",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-13",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Jeffrey Kern",
                "investigatorTitle": "Professor of Medicine",
                "investigatorAffiliation": "National Jewish Health"
            },
            "leadSponsor": {
                "name": "National Jewish Health",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Memorial Sloan Kettering Cancer Center",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This protocol is a prospective, observational study of participants receiving immunotherapy (checkpoint inhibitors, CPI) for cancer therapy, testing the hypothesis that patients with immune related cutaneous adverse events (ircAEs) have unique immunologic endotypes associated with polarized immune responses."
        },
        "conditionsModule": {
            "conditions": [
                "Cancer"
            ],
            "keywords": [
                "checkpoint inhibitor",
                "immuno-oncology",
                "cutaneous adverse events"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 238,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "CPI with ircAE",
                    "description": "Participants on check point inhibitors with immune related cutaneous adverse event",
                    "interventionNames": [
                        "Drug: systemic corticosteroid or biologic"
                    ]
                },
                {
                    "label": "no ircAE",
                    "description": "Participants who do not have a cutaneous adverse event"
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "systemic corticosteroid or biologic",
                    "description": "Treatment with systemic corticosteroids or biologic therapies (for corticosteroid refractory patients or these in which corticosteroids are not the treatment of choice)",
                    "armGroupLabels": [
                        "CPI with ircAE"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Immune Biomarkers",
                    "description": "cytokines and chemokines",
                    "timeFrame": "30 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Presence of skin and circulating lipid biomarkers which occur during and after ircAEs",
                    "description": "Proportion of long-chain and short-chain ceramides Amounts and relative proportion of lysophosphatidylcholine molecular species. sphingosine-1-phosphate, platelet activating factor, leukotriene E4, prostaglandin F2\u03b1, endocannabinoids anandamide and 2- arachidonoylglycerol.\n\nPeripheral blood mononuclear cell RNA for expression of GRalpha, GRbeta, Vitamin D 24- Hydroxylase FK506 binding protein 5, mitogen induced kinase phosphatase 1, interleukin, tumor necrosis factor alphal",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "Mechanisms associated with corticosteroid unresponsiveness in patients with ircAE",
                    "description": "Proportion of long-chain and short-chain ceramides Amounts and relative proportion of lysophosphatidylcholine molecular species. sphingosine-1-phosphate, platelet activating factor, leukotriene E4, prostaglandin F2\u03b1, endocannabinoids anandamide and 2- arachidonoylglycerol.\n\nPeripheral blood mononuclear cell RNA for expression of GRalpha, GRbeta, Vitamin D 24- Hydroxylase FK506 binding protein 5, mitogen induced kinase phosphatase 1, interleukin, tumor necrosis factor alphal",
                    "timeFrame": "12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, \\>18 yo\n4. Diagnosis of solid tumor including, but not limited to, genitourinary/gynecologic, lung, gastrointestinal and melanoma\n5. Receiving, or prior to starting on, a checkpoint inhibitor\n6. Grade \u2265 2 ircAE (CTCAE v 5.0) (for cohort 1 only)\n7. An indication for system corticosteroids or biologic therapies as determined by the treating physician (for cohort 1 only)\n8. Life expectancy \u2265 12 weeks\n\nExclusion Criteria:\n\n1. Daily use of systemic steroid treatment in the past 4 weeks (prednisone \\>10mg a day or equivalent) except for indications other than the cutaneous adverse event, and/or as an anti-emetic pre- or post-chemotherapy infusions.\n2. Enrollment in any investigational drug trial with a drug that has not been approved\n3. Taking other checkpoint inhibitors beyond anti-PD-(L)-1 or anti-CTLA-4 not yet indicated/approved for use\n4. Pregnancy\n5. Known blood borne infectious disease\n6. Current or pervious diagnosis of a leukemia or lymphoma\n7. Unable to give consent for study participation\n8. Life expectancy \\< 12 weeks\n9. Any other condition or diagnosis in the opinion of the investigator that would interfere with the study results",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Adult male or female with diagnosis of solid tumor",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Joanne Streib",
                    "role": "CONTACT",
                    "phone": "303-398-1731",
                    "email": "streibj@njhealth.org"
                }
            ],
            "locations": [
                {
                    "facility": "National Jewish Health",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80206",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Daniell Plomondon",
                            "role": "CONTACT",
                            "phone": "303-270-2488",
                            "email": "plomondond@njhealth.org"
                        },
                        {
                            "name": "Jeffrey Kern, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "The Melanoma and Skin Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80206",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ryan Weight, DO",
                            "role": "CONTACT",
                            "phone": "720-319-8091",
                            "email": "ryan.weight@theskincancerinstitute.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mario Lacouture, MD",
                            "role": "CONTACT",
                            "phone": "646-608-2337",
                            "email": "LacoutuM@mskcc.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}